MSR6 Modeling Survival of People with Cystic Fibrosis (PWCF) Aged ≥6 Years Heterozygous for the F508DEL Mutation with a Minimal Function Mutation (F/MF) in Brazil Treated with Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor (ELX/TEZ/IVA)
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.1213
https://www.valueinhealthjournal.com/article/S1098-3015(22)01414-0/fulltext
Title :
MSR6 Modeling Survival of People with Cystic Fibrosis (PWCF) Aged ≥6 Years Heterozygous for the F508DEL Mutation with a Minimal Function Mutation (F/MF) in Brazil Treated with Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor (ELX/TEZ/IVA)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)01414-0&doi=10.1016/j.jval.2022.04.1213
First page :
Section Title :
Open access? :
No
Section Order :
11082